Primary endocrine therapy for advanced breast cancer: To start with tamoxifen or with medroxyprogesterone acetate?-Reference-Cited by-同舟云学术

Primary endocrine therapy for advanced breast cancer: To start with tamoxifen or with medroxyprogesterone acetate?

Published:1993-11 Issue:9 Volume:4 Page:735-740
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Castiglione-Gertsch M.,Pampallona S.,Varini M.,Cavalli F.,Brunner K.,Senn H.J.,Goldhirsch A.,Metzger U.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/4/9/735/407545/4-9-735.pdf

Reference19 articles.

1. Bailliere’s Clinical Oncology;Goldhirsch;International Practice and Research. Breast Cancer,1988

2. Tamoxifen in advanced breast cancer;Mouridsen;Cancer Treat Rev,1978

3. The value of estrogen and progesterone receptors in the treatment of breast cancer;Osborne;Cancer,1980

4. The role of progesterone receptors in the management of advanced breast cancer;Bloom;Cancer,1980

5. Serum level profile of medroxyprogesterone acetate in breast cancer patients treated intramuscularly with two different dose schedule;Goldhirsch,1981

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside;ENDOCRINOLOGY;2021

2. Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside;Endocrinology;2021-09-04

3. Expanding Treatment Arsenal for Oestrogen Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer;Hong Kong Journal of Radiology;2019-07-08

4. Human versus non-human sex steroid use in hormone replacement therapies part 1: Preclinical data;Molecular and Cellular Endocrinology;2019-01

5. Hormone replacement therapy after cancers;Current Opinion in Internal Medicine;2005-12